MEF-2 isoforms’ (A-D) roles in development and tumorigenesis
Metrics: PDF 44 views | HTML 88 views | ?
Kiran Madugula1, Ria Mulherkar1, Zafar K. Khan1, DeGaulle I. Chigbu1, Dip Patel1, Edward W. Harhaj2 and Pooja Jain1
1Department of Microbiology and Immunology, the Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA 19129, USA
2Department of Microbiology and Immunology, Penn State College of Medicine, Hershey, PA 17033, USA
Pooja Jain, email: email@example.com
Keywords: MEF-2; HDACs; HDACi; HTLV-1; ATLL
Received: November 26, 2018 Accepted: February 01, 2019 Published: April 12, 2019
Myocyte enhancer factor (MEF)-2 plays a critical role in proliferation, differentiation, and development of various cell types in a tissue specific manner. Four isoforms of MEF-2 (A-D) differentially participate in controlling the cell fate during the developmental phases of cardiac, muscle, vascular, immune and skeletal systems. Through their associations with various cellular factors MEF-2 isoforms can trigger alterations in complex protein networks and modulate various stages of cellular differentiation, proliferation, survival and apoptosis. The role of the MEF-2 family of transcription factors in the development has been investigated in various cell types, and the evolving alterations in this family of transcription factors have resulted in a diverse and wide spectrum of disease phenotypes, ranging from cancer to infection. This review provides a comprehensive account on MEF-2 isoforms (A-D) from their respective localization, signaling, role in development and tumorigenesis as well as their association with histone deacetylases (HDACs), which can be exploited for therapeutic intervention.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.